GlassScriptPhysician profile
Joanna L Chan
NPI 1588714430
$18,095.53
in general payments reported to CMS, 2019-2025
42 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 90% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,891 · 2020: $641 · 2021: $2,773 · 2022: $1,724 · 2023: $2,633 · 2024: $5,101 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,994 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,993.98 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,533.16 | 2020-2025 | |
| Abbvie INC. | $2,252.50 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Lumenis Be INC | $1,185.18 | 2024 | M22 |
| Dermavant Sciences, INC. | $1,097.74 | 2023-2024 | Vtama |
| Pfizer INC. | $1,052.80 | 2019-2025 | |
| Merz North America, INC. | $1,052.40 | 2022-2025 | Xeomin |
| Almirall LLC | $775.75 | 2019-2025 | Klisyri, Seysara |
| Allergan, INC. | $693.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $676.70 | 2023-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $663.76 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $632.79 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $563.56 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Galderma Laboratories, L.P. | $397.62 | 2019-2024 | Epsolay, Aklief, Oracea |
| Janssen Biotech, INC. | $361.83 | 2019-2025 | Tremfya |
| Incyte Corporation | $323.98 | 2022-2025 | Opzelura |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $307.58 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $229.87 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $207.62 | 2019-2024 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $193.16 | 2023-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $188.34 | 2019-2023 | Erivedge |
| Organon LLC | $157.43 | 2025 | Vtama |
| Botanix Sb INC | $147.48 | 2025 | Sofdra |
| Journey Medical Corporation | $142.54 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $137.85 | 2019-2021 | |
| Revance Therapeutics, INC. | $137.28 | 2024-2025 | Daxxify |
| Silk Road Medical, INC. | $136.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $126.78 | 2019-2025 | |
| Cook Medical LLC | $120.04 | 2019 | |
| Amgen INC. | $96.88 | 2020-2025 | Otezla, Otezla |
| Bolton Medical INC | $89.90 | 2022 | |
| Epi Health, LLC | $61.96 | 2019-2020 | |
| Organogenesis INC. | $52.78 | 2024 | Apligraf |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.18 | 2024 | Spevigo, Cyltezo |
| Sanofi-Aventis U.S. LLC | $45.61 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Biofrontera INC. | $40.32 | 2019 | |
| Misonix INC | $27.37 | 2021 | |
| Novo Nordisk INC | $22.93 | 2025 | Rybelsus, Ozempic |
| Dermira, INC. | $20.41 | 2019 | |
| Sumitomo Pharma America, INC. | $19.84 | 2024 | Gemtesa |
| Nabriva Therapeutics, Plc | $14.32 | 2021 | |
| Celgene Corporation | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.